Cargando…
Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus
BACKGROUND: Enhancement of myocardial glucose uptake may reduce fatty acid oxidation and improve tolerance to ischemia. Hyperglycemia, in association with hyperinsulinemia, stimulates this metabolic change but may have deleterious effects on left ventricular (LV) function. The incretin hormone, gluc...
Autores principales: | McCormick, Liam M, Heck, Patrick M, Ring, Liam S, Kydd, Anna C, Clarke, Sophie J, Hoole, Stephen P, Dutka, David P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528379/ https://www.ncbi.nlm.nih.gov/pubmed/26253538 http://dx.doi.org/10.1186/s12933-015-0259-3 |
Ejemplares similares
-
Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1
por: Clarke, Sophie J, et al.
Publicado: (2014) -
Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies
por: Giblett, Joel P., et al.
Publicado: (2016) -
Hyperinsulinemia improves ischemic LV function in insulin resistant subjects
por: Heck, Patrick M, et al.
Publicado: (2010) -
Glucagon-Like Peptide-1: A Promising Agent for Cardioprotection During Myocardial Ischemia
por: Giblett, Joel P., et al.
Publicado: (2016) -
Glucagon-Like Peptide-1–Mediated Cardioprotection Does Not Reduce Right Ventricular Stunning and Cumulative Ischemic Dysfunction After Coronary Balloon Occlusion
por: Giblett, Joel P., et al.
Publicado: (2019)